Soleno Therapeutics Announces Inducement Grants
Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company focused on creating innovative treatments for rare diseases, has revealed that it has granted inducement awards to six new employees, in accordance with Nasdaq Stock Market regulations.
Details of the Inducement Awards
The independent members of Soleno's Board of Directors have given their approval for the issuance of non-qualified stock options, enabling the purchase of 143,850 shares of common stock. This initiative is designed to encourage the new employees to join Soleno, consistent with Nasdaq Listing Rule 5635(c)(4).
The options will feature an exercise price of $49.52 and $48.44 per share, which correspond to the closing prices of Soleno's common stock on the Nasdaq Stock Market on specific dates prior to the grants. The vesting schedule for these options extends over four years, with 25% of the shares vesting on the one-year anniversary of the grant date. After that, an additional 1/48th of the shares will vest each month for the remainder of the vesting period, provided the new employee remains with the company.
About Soleno Therapeutics, Inc.
Soleno is dedicated to the development and commercialization of innovative therapeutics aimed at rare diseases. Recently, the company submitted a New Drug Application (NDA) to the FDA, backed by the results of its Phase 3 development program, for its leading candidate, DCCR (diazoxide choline) extended-release tablets. This oral medication is intended for once-daily use to treat Prader-Willi syndrome (PWS), showcasing Soleno's commitment to meeting unmet medical needs.
If you have any questions, please refer to the corporate contact information provided below.
Corporate Contact
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
Frequently Asked Questions
1. What are the inducement grants mentioned in the article?
The inducement grants refer to stock options awarded to six new employees of Soleno Therapeutics as part of their employment agreement, in compliance with Nasdaq rules.
2. What is the significance of these stock options?
The stock options serve as an incentive for new employees to join Soleno and align their interests with the long-term success of the company.
3. How many shares are involved in the inducement awards?
There are a total of 143,850 shares of common stock involved in the inducement awards granted to the new employees.
4. What is the vesting schedule for the stock options?
The options will vest over a four-year period, with 25% vesting on the one-year anniversary and the remaining shares vesting monthly thereafter.
5. What therapeutic area does Soleno Therapeutics focus on?
Soleno Therapeutics focuses on developing therapeutics for rare diseases, with a recent emphasis on treatments for Prader-Willi syndrome (PWS).
